DrugPatentWatch Database Preview
Drugs in Development Information for GWP42003-P
Email this page to a colleague
What is the development status for investigational drug GWP42003-P?
GWP42003-P is an investigational drug.
There have been 27 clinical trials for GWP42003-P.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 9th 2019.
The most common disease conditions in clinical trials are Syndrome, Seizures, and Lennox Gastaut Syndrome. The leading clinical trial sponsors are GW Research Ltd, University of Colorado, Denver, and Colorado Department of Public Health and Environment.
There is one US patent protecting this investigational drug and five international patents.
Summary for GWP42003-P
| US Patents | 1,109 |
| International Patents | 5,351 |
| US Patent Applications | 4,317 |
| WIPO Patent Applications | 2,035 |
| Japanese Patent Applications | 398 |
| Clinical Trial Progress | Phase 3 (2019-12-09) |
| Vendors | 29 |
Recent Clinical Trials for GWP42003-P
| Title | Sponsor | Phase |
|---|---|---|
| Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder | GW Research Ltd | Phase 2 |
| Safety, Pharmacokinetics, and Exploratory Efficacy Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared With Standard of Care Antiepileptic Therapy, in Patients Age 1 Month to <12 Months of Age With Tuberous Sclerosis Complex Who | GW Research Ltd | Phase 3 |
| Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment | GW Research Ltd | Phase 2 |
Clinical Trial Summary for GWP42003-P
Top disease conditions for GWP42003-P
Top clinical trial sponsors for GWP42003-P
US Patents for GWP42003-P
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GWP42003-P | Try Before You Buy | Pharmaceutical formulations | GW Pharma Limited (Cambridge, GB) | Try Before You Buy |
| GWP42003-P | Try Before You Buy | Compositions and methods for treating chronic inflammation and inflammatory diseases | Infirst Healthcare Limited (London, GB) | Try Before You Buy |
| GWP42003-P | Try Before You Buy | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | KANNALIFE SCIENCES, INC. (Huntington, NY) | Try Before You Buy |
| GWP42003-P | Try Before You Buy | METAP2 inhibitors and methods of treating obesity | SynDevRx, Inc. (Cambridge, MA) | Try Before You Buy |
| GWP42003-P | Try Before You Buy | Pre-spray emulsions and powders containing non-polar compounds | Virun, Inc. (Pomona, CA) | Try Before You Buy |
| GWP42003-P | Try Before You Buy | CB2 receptor ligands for the treatment of psychiatric disorders | Anavi-Goffer; Sharon (Oranit, IL) | Try Before You Buy |
| GWP42003-P | Try Before You Buy | Transdermal cannabinoid formulations | Wisconsin Alumni Research Foundation (Madison, WI) | Try Before You Buy |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GWP42003-P
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GWP42003-P | Australia | AU2002231970 | 2021-02-14 | Try Before You Buy |
| GWP42003-P | Canada | CA2438097 | 2021-02-14 | Try Before You Buy |
| GWP42003-P | Canada | CA2533400 | 2021-02-14 | Try Before You Buy |
| GWP42003-P | China | CN1886117 | 2021-02-14 | Try Before You Buy |
| GWP42003-P | Cyprus | CY1115072 | 2021-02-14 | Try Before You Buy |
| GWP42003-P | Czech Republic | CZ20032458 | 2021-02-14 | Try Before You Buy |
| GWP42003-P | Czech Republic | CZ306277 | 2021-02-14 | Try Before You Buy |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
